{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:56:32Z","timestamp":1790927792884,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2022R1A2C1010531"],"award-info":[{"award-number":["NRF-2022R1A2C1010531"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00350775"],"award-info":[{"award-number":["RS-2024-00350775"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00279216"],"award-info":[{"award-number":["RS-2023-00279216"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2019R1A5A2027588"],"award-info":[{"award-number":["2019R1A5A2027588"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-02310437"],"award-info":[{"award-number":["RS-2025-02310437"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-00553500"],"award-info":[{"award-number":["RS-2025-00553500"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00217798"],"award-info":[{"award-number":["RS-2023-00217798"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    N-terminal acetyltransferase D (NatD) acetylates histones H4 and H2A at serine 1 and has been implicated in oncogenesis, yet its role in glioblastoma (GBM) remains unexplored. Here, we show that NatD expression is significantly elevated in GBM at both transcript and protein levels. NatD knockdown markedly suppressed proliferation, colony formation, migration, invasion and tumoursphere formation in GBM cell lines and patient-derived models, indicating a critical role in maintaining cancer stem-like properties. These inhibitory effects were rescued by reintroduction of wild-type NatD but not by a catalytically inactive mutant, confirming dependence on its enzymatic activity. Transcriptomic profiling identified fibroblast growth factor receptor (FGFR) 4 as a key downstream effector. Mechanistically, NatD maintained N-terminal acetylation of histones H4 and H2A at the\n                    <jats:italic>FGFR4<\/jats:italic>\n                    promoter, thereby antagonizing casein kinase 2\u03b1-mediated phosphorylation and sustaining an open chromatin state permissive for transcription. NatD depletion reduced FGFR4 expression and downstream ERK1\/2 and AKT phosphorylation, whereas FGFR4 overexpression restored malignant phenotypes suppressed by NatD knockdown both in vitro and in xenograft models. Orthotopic xenograft models further demonstrated that NatD depletion suppresses intracranial tumour growth and prolongs survival, whereas FGFR4 re-expression partially restores tumour progression. Analysis of TCGA GBM datasets revealed that the positive correlation between\n                    <jats:italic>NatD<\/jats:italic>\n                    and\n                    <jats:italic>FGFR4<\/jats:italic>\n                    expression is maintained across multiple molecular subtypes. Collectively, these findings identify NatD as an oncogenic regulator of GBM and underscore NatD\u2013FGFR4 signalling as a promising therapeutic target.\n                  <\/jats:p>","DOI":"10.1038\/s12276-026-01818-9","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:57:29Z","timestamp":1788335849000},"page":"2938-2950","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NatD promotes glioblastoma progression through epigenetic activation of FGFR4 signalling"],"prefix":"10.1038","volume":"58","author":[{"given":"Chan-Woo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taek-Yeol","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4911-352X","authenticated-orcid":false,"given":"Chanil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EungHan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heui Og","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyeon","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyelee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga-Yeon","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Jung","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehyuk","family":"Pyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Taeg","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dokyeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0436-8614","authenticated-orcid":false,"given":"Junseong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minji","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-2037","authenticated-orcid":false,"given":"Seok-Gu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Bae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7360-429X","authenticated-orcid":false,"given":"Chul Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1128-892X","authenticated-orcid":false,"given":"Seung-Hyun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sug Hyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2121-6655","authenticated-orcid":false,"given":"Ho-Shik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8441-396X","authenticated-orcid":false,"given":"Hyun-Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"1818_CR1","first-page":"1231","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neurooncology 23, 1231\u20131251 (2021).","journal-title":"Neurooncology"},{"key":"1818_CR2","first-page":"299","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan, A. C. et al. Management of glioblastoma: state of the art and future directions. CA Cancer J. Clin. 70, 299\u2013312 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"1818_CR3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1818_CR4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jocn.2018.05.002","volume":"54","author":"T Tykocki","year":"2018","unstructured":"Tykocki, T. & Eltayeb, M. Ten-year survival in glioblastoma. A systematic review. J. Clin. Neurosci. 54, 7\u201313 (2018).","journal-title":"J. Clin. Neurosci."},{"key":"1818_CR5","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462\u2013477 (2013).","journal-title":"Cell"},{"key":"1818_CR6","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/cac2.12361","volume":"42","author":"E Verdugo","year":"2022","unstructured":"Verdugo, E., Puerto, I. & Medina, M. A. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment. Cancer Commun. 42, 1083\u20131111 (2022).","journal-title":"Cancer Commun."},{"key":"1818_CR7","volume":"5","author":"P Sharma","year":"2023","unstructured":"Sharma, P., Aaroe, A., Liang, J. & Puduvalli, V. K. Tumor microenvironment in glioblastoma: current and emerging concepts. Neurooncol. Adv. 5, vdad009 (2023).","journal-title":"Neurooncol. Adv."},{"key":"1818_CR8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2022.09.005","volume":"9","author":"A Bikfalvi","year":"2023","unstructured":"Bikfalvi, A. et al. Challenges in glioblastoma research: focus on the tumor microenvironment. Trends Cancer 9, 9\u201327 (2023).","journal-title":"Trends Cancer"},{"key":"1818_CR9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.semcancer.2020.12.015","volume":"83","author":"MS Uddin","year":"2022","unstructured":"Uddin, M. S. et al. Epigenetics of glioblastoma multiforme: from molecular mechanisms to therapeutic strategies. Semin. Cancer Biol. 83, 100\u2013120 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"1818_CR10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.602378","volume":"10","author":"LM Valor","year":"2020","unstructured":"Valor, L. M. & Herv\u00e1s-Corpi\u00f3n, I. The epigenetics of glioma stem cells: a brief overview. Front. Oncol. 10, 602378 (2020).","journal-title":"Front. Oncol."},{"key":"1818_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00735-9","volume":"13","author":"L Zhang","year":"2025","unstructured":"Zhang, L. et al. Epigenetic regulation of histone modifications in glioblastoma: recent advances and therapeutic insights. Biomark. Res. 13, 20 (2025).","journal-title":"Biomark. Res."},{"key":"1818_CR12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26125634","volume":"26","author":"M Meleiro","year":"2025","unstructured":"Meleiro, M. & Henrique, R. Epigenetic alterations in glioblastoma multiforme as novel therapeutic opportunities. Int. J. Mol. Sci. 26, 5634 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1818_CR13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7150\/thno.8799","volume":"5","author":"R Pacaud","year":"2015","unstructured":"Pacaud, R., Cheray, M., Nadaradjane, A., Vallette, F. M. & Cartron, P. F. Histone H3 phosphorylation in GBM: a new rational to guide the use of kinase inhibitors in anti-GBM therapy. Theranostics 5, 12\u201322 (2015).","journal-title":"Theranostics"},{"key":"1818_CR14","volume":"10","author":"D Wu","year":"2020","unstructured":"Wu, D., Qiu, Y., Jiao, Y., Qiu, Z. & Liu, D. Small molecules targeting HATs, HDACs, and BRDs in cancer therapy. Front. Oncol. 10, 560487 (2020).","journal-title":"Front. Oncol."},{"key":"1818_CR15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.tips.2024.01.010","volume":"45","author":"J White","year":"2024","unstructured":"White, J. et al. Histone lysine acetyltransferase inhibitors: an emerging class of cancer therapeutics. Trends Pharmacol. Sci. 45, 233\u2013247 (2024).","journal-title":"Trends Pharmacol. Sci."},{"key":"1818_CR16","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217269","volume":"604","author":"S Pathikonda","year":"2024","unstructured":"Pathikonda, S., Amirmahani, F., Mathew, D. & Muthukrishnan, S. D. Histone acetyltransferases as promising therapeutic targets in glioblastoma resistance. Cancer Lett. 604, 217269 (2024).","journal-title":"Cancer Lett."},{"key":"1818_CR17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2990.2010.01132.x","volume":"37","author":"F Orzan","year":"2011","unstructured":"Orzan, F. et al. Enhancer of zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol. Appl. Neurobiol. 37, 381\u2013394 (2011).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"1818_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03380-2","volume":"12","author":"DH Lee","year":"2021","unstructured":"Lee, D. H. et al. Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc. Cell Death Dis. 12, 89 (2021).","journal-title":"Cell Death Dis."},{"key":"1818_CR19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3390\/jmp4040018","volume":"4","author":"MA Azab","year":"2023","unstructured":"Azab, M. A. The potential role of histone modifications in glioblastoma therapy: review article. J. Mol. Pathol. 4, 196\u2013212 (2023).","journal-title":"J. Mol. Pathol."},{"key":"1818_CR20","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.260801","volume":"136","author":"M Constantinou","year":"2023","unstructured":"Constantinou, M. et al. Cellular effects of NAT-mediated histone N-terminal acetylation. J. Cell Sci. 136, jcs260801 (2023).","journal-title":"J. Cell Sci."},{"key":"1818_CR21","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.molcel.2019.02.007","volume":"73","author":"H Aksnes","year":"2019","unstructured":"Aksnes, H., Ree, R. & Arnesen, T. Co-translational, post-translational, and non-catalytic roles of n-terminal acetyltransferases. Mol. Cell 73, 1097\u20131114 (2019).","journal-title":"Mol. Cell"},{"key":"1818_CR22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092631","volume":"12","author":"C Koufaris","year":"2020","unstructured":"Koufaris, C. & Kirmizis, A. N-terminal acetyltransferases are cancer-essential genes prevalently upregulated in tumours. Cancers 12, 2631 (2020).","journal-title":"Cancers"},{"key":"1818_CR23","volume":"754","author":"H Wu","year":"2025","unstructured":"Wu, H. et al. N-terminal histone acetyltransferase NAA40 modulates osteosarcoma progression by controlling AGR2 expression. Biochem. Biophys. Res. Commun. 754, 151491 (2025).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1818_CR24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41388-021-02113-9","volume":"41","author":"C Demetriadou","year":"2022","unstructured":"Demetriadou, C. et al. Histone N-terminal acetyltransferase NAA40 links one-carbon metabolism to oncogenesis in colorectal cancer. Oncogene 41, 214\u2013227 (2022).","journal-title":"Oncogene"},{"key":"1818_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00988-5","volume":"8","author":"J Ju","year":"2017","unstructured":"Ju, J. et al. NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate slug expression. Nat. Commun. 8, 928 (2017).","journal-title":"Nat. Commun."},{"key":"1818_CR26","volume":"27","author":"X Xing","year":"2024","unstructured":"Xing, X. et al. NatD epigenetically activates FOXA2 expression to promote breast cancer progression via MMP14 axis. iScience 27, 108840 (2024).","journal-title":"iScience"},{"key":"1818_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep16033","volume":"5","author":"D Pavlou","year":"2015","unstructured":"Pavlou, D. et al. Depletion of histone N-terminal-acetyltransferase Naa40 induces p53-independent apoptosis in colorectal cancer cells. Sci. Rep. 5, 16033 (2015).","journal-title":"Sci. Rep."},{"key":"1818_CR28","volume":"2","author":"C Koufaris","year":"2021","unstructured":"Koufaris, C. & Kirmizis, A. Identification of NAA40 as a potential prognostic marker for aggressive liver cancer subtypes. Front. Oncol. 2, 11 (2021).","journal-title":"Front. Oncol."},{"key":"1818_CR29","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.str.2014.10.025","volume":"23","author":"RS Magin","year":"2015","unstructured":"Magin, R. S., Liszczak, G. P. & Marmorstein, R. The molecular basis for histone H4- and H2A-specific amino-terminal acetylation by NatD. Structure 23, 332\u2013341 (2015).","journal-title":"Structure"},{"key":"1818_CR30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"IS Babina","year":"2017","unstructured":"Babina, I. S. & Turner, N. C. Advances and challenges in targeting FGFR signalling in cancer. Nat. Rev. Cancer 17, 318\u2013332 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"1818_CR31","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1159\/000487737","volume":"45","author":"J Huang","year":"2018","unstructured":"Huang, J. et al. TGF-\u03b21 promotes hepatocellular carcinoma invasion and metastasis via ERK pathway-mediated FGFR4 expression. Cell Physiol. Biochem. 45, 1690\u20131699 (2018).","journal-title":"Cell Physiol. Biochem."},{"key":"1818_CR32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123825","volume":"12","author":"A Ardizzone","year":"2020","unstructured":"Ardizzone, A. et al. Role of fibroblast growth factors receptors (FGFRs) in brain tumors, focus on astrocytoma and glioblastoma. Cancers 12, 3825 (2020).","journal-title":"Cancers"},{"key":"1818_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-022-01363-2","volume":"10","author":"L Gabler","year":"2022","unstructured":"Gabler, L. et al. Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness. Acta Neuropathol. Commun. 10, 65 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"1818_CR34","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cub.2005.02.049","volume":"15","author":"WL Cheung","year":"2005","unstructured":"Cheung, W. L. et al. Phosphorylation of histone H4 serine 1 during DNA damage requires casein kinase II in S. cerevisiae. Curr. Biol. 15, 656\u2013660 (2005).","journal-title":"Curr. Biol."},{"key":"1818_CR35","volume":"848","author":"R Zhu","year":"2024","unstructured":"Zhu, R. et al. The role of N-acetyltransferases in cancers. Gene 848, 146865 (2024).","journal-title":"Gene"},{"key":"1818_CR36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","volume":"16","author":"VP Eswarakumar","year":"2005","unstructured":"Eswarakumar, V. P., Lax, I. & Schlessinger, J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16, 139\u2013149 (2005).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1818_CR37","volume":"8","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Dissecting the role of the FGF19-FGFR4 signaling pathway in cancer development and progression. Front. Cell Dev. Biol. 8, 95 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"1818_CR38","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41388-019-0997-x","volume":"39","author":"T Schaefer","year":"2020","unstructured":"Schaefer, T. & Lengerke, C. SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3K\/AKT\/SOX2 axis and beyond. Oncogene 39, 278\u2013292 (2020).","journal-title":"Oncogene"},{"key":"1818_CR39","volume":"10","author":"S Singh","year":"2025","unstructured":"Singh, S. et al. Glioblastoma at the crossroads: current understanding and future therapeutic horizons. Signal. Transduct. Target. Ther. 10, 213 (2025).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1818_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-45774-0","volume":"13","author":"H Liu","year":"2023","unstructured":"Liu, H. & Tang, T. MAPK signaling pathway-based glioma subtypes, machine-learning risk model, and key hub proteins identification. Sci. Rep. 13, 19055 (2023).","journal-title":"Sci. Rep."},{"key":"1818_CR41","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.stem.2009.08.018","volume":"5","author":"H Ikushima","year":"2009","unstructured":"Ikushima, H. et al. Autocrine TGF-\u03b2 signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-Box factors. Cell Stem Cell 5, 504\u2013514 (2009).","journal-title":"Cell Stem Cell"},{"key":"1818_CR42","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ccr.2009.02.011","volume":"15","author":"S Pe\u00f1uelas","year":"2009","unstructured":"Pe\u00f1uelas, S. et al. TGF-\u03b2 increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15, 315\u2013327 (2009).","journal-title":"Cancer Cell"},{"key":"1818_CR43","doi-asserted-by":"crossref","first-page":"L818","DOI":"10.1152\/ajplung.00184.2023","volume":"327","author":"M Ghanem","year":"2024","unstructured":"Ghanem, M. et al. Identification of FGFR4 as a regulator of myofibroblast differentiation in pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 327, L818\u2013L830 (2024).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1818_CR44","volume":"12","author":"C Sun","year":"2022","unstructured":"Sun, C. et al. Functions of exogenous FGF signals in regulation of fibroblast to myofibroblast. Open Biol. 12, 210356 (2022).","journal-title":"Open Biol."},{"key":"1818_CR45","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022277","volume":"9","author":"J Seoane","year":"2017","unstructured":"Seoane, J. & Gomis, R. R. TGF-\u03b2 family signaling in tumor suppression and cancer progression. Cold Spring Harb. Perspect. Biol. 9, a022277 (2017).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1818_CR46","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10014-025-00505-3","volume":"42","author":"S Sadeghzadeh","year":"2025","unstructured":"Sadeghzadeh, S. et al. Targeting TGF\u2011\u03b2 signaling in glioblastoma: therapeutic implications and novel drug development strategies. Brain Tumor Pathol. 42, 105\u2013120 (2025).","journal-title":"Brain Tumor Pathol."},{"key":"1818_CR47","first-page":"1850","volume":"26","author":"A Hou","year":"2024","unstructured":"Hou, A. et al. IL-13R\u03b12\/TGF-\u03b2 bispecific CAR-T cells counter TGF-\u03b2-mediated immune suppression and potentiate anti-tumor responses in glioblastoma. Neurooncology 26, 1850\u20131866 (2024).","journal-title":"Neurooncology"},{"key":"1818_CR48","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle, E. & Massague, J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity 50, 924\u2013940 (2019).","journal-title":"Immunity"},{"key":"1818_CR49","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"1818_CR50","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40265-019-01142-9","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham, A. Erdafitinib: first global approval. Drugs 79, 1017\u20131021 (2019).","journal-title":"Drugs"},{"key":"1818_CR51","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","volume":"12","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam, F. et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study. Cancer Discov. 12, 402\u2013415 (2022).","journal-title":"Cancer Discov."},{"key":"1818_CR52","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RGW Verhaak","year":"2010","unstructured":"Verhaak, R. G. W. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98\u2013110 (2010).","journal-title":"Cancer Cell"},{"key":"1818_CR53","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis, C. D., Ferraro, G. B. & Jain, R. K. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat. Rev. Cancer 20, 26\u201341 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"1818_CR54","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1021\/acs.jmedchem.1c00141","volume":"64","author":"Y Deng","year":"2021","unstructured":"Deng, Y. et al. Novel bisubstrate inhibitors for protein N-terminal acetyltransferase D. J. Med. Chem. 64, 8263\u20138271 (2021).","journal-title":"J. Med. Chem."},{"key":"1818_CR55","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1021\/acschembio.5c00666","volume":"20","author":"YS Ho","year":"2025","unstructured":"Ho, Y. S., Seipp, E. K., Lamdate, T. & Huang, R. A cell-potent bisubstrate inhibitor to probe NatD acetyltransferase activity. ACS Chem. Biol. 20, 2512\u20132020 (2025).","journal-title":"ACS Chem. Biol."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01818-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01818-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01818-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:39:02Z","timestamp":1790926742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01818-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":55,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1818"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01818-9","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}